Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,691,938

« Back to Dashboard

Which drugs does patent 8,691,938 protect, and when does it expire?


Patent 8,691,938 protects VIEKIRA PAK (COPACKAGED), VIEKIRA XR, and TECHNIVIE, and is included in three NDAs.

This patent has one hundred and ninety-one patent family members in forty countries.

Summary for Patent: 8,691,938

Title:Anti-viral compounds
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s): DeGoey; David A. (Salem, WI), Kati; Warren M. (Gurnee, IL), Hutchins; Charles W. (Green Oaks, IL), Donner; Pamela L. (Mundelein, IL), Krueger; Allan C. (Gurnee, IL), Randolph; John T. (Libertyville, IL), Motter; Christopher E. (Oak Creek, WI), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Matulenko; Mark A. (Libertyville, IL), Keddy; Ryan G. (Beach Park, IL), Jinkerson; Tammie K. (Pleasant Prairie, WI), Gao; Yi (Vernon Hills, IL), Liu; Dachun (Vernon Hills, IL), Pratt; John K. (Kenosha, WI), Rockway; Todd W. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Hutchinson; Douglas K. (Antioch, IL), Flentge; Charles A. (Salem, WI), Wagner; Rolf (Antioch, IL), Tufano; Michael D. (Chicago, IL), Betebenner; David A. (Grayslake, IL), Sarris; Kathy (Mundelein, IL), Woller; Kevin R. (Antioch, IL), Wagaw; Seble H. (Evanston, IL), Califano; Jean C. (Whitefish Bay, WI), Li; Wenke (Gurnee, IL), Caspi; Daniel D. (Evanston, IL), Bellizzi; Mary E. (Lake Forest, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:12/813,301
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,691,938► SubscribeYY
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes8,691,938► SubscribeYY
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes8,691,938► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,691,938

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,394,279Anti-viral compounds► Subscribe
8,921,514Anti-viral compounds► Subscribe
8,686,026Solid compositions► Subscribe
9,023,8782-iminobiotin formulations and uses thereof► Subscribe
9,006,387Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,691,938

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia2368890► Subscribe
Singapore188951► Subscribe
Singapore186251► Subscribe
Singapore171708► Subscribe
Russian Federation2013152229► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot